Madrid hosts the second congress of the first Spanish company that works to raise awareness of this discipline
The new minimally invasive methods for diagnosis and treatment of oral diseases dental visits will end up conquering Spanish. More and more professionals that are seeking a clinical practice based on noninvasive methods to meet the growing demand of patients seeking treatments that are not aggressive.
The minimally invasive approach encompasses all aspects of dentistry, promoting the practice of non-aggressive oral therapy. Starting from the premise that the most important thing is to preserve the original fabric, the concept embraces both the procedures for early diagnosis and treatment of disease, risks and associated symptoms, the latter prerequisite for final processing to produce a minimally invasive and therefore minimal trauma to the patient.
This new understanding of dentistry can be applied in the treatment of oral diseases such as caries, periodontal disease, occlusal wear, prosthodontic reconstruction, rehabilitation with implants, among many other procedures. Experts believe that we have a renewing vision of dentistry in which the patient has a high profile, while is committed to improving both their oral health dental and general health status.
What is minimally invasive dentistry?
discipline that promotes the maintenance of oral and dental health through diagnosis and aggressive treatment of minimal.
incorporates the latest technology to achieve the best clinical treatments.
anticipates demand for the patient, offering maximum effectiveness with minimal intervention.
adopting this philosophy of work, career progress is being made to the future.
Seomi, the first society of minimally invasive dentistry
In order to present minimally invasive dentistry, Seomi held the second congress of the first Spanish Society of Minimally Invasive Dentistry (Seomi), a non-profit organization that seeks to become a forum for the exchange and development of concepts own practice minimally invasive. To fulfill these purposes, Seomi performs the following activities:
sharing information and experiences
internal training and development of their members
Innovation in clinical skills
research projects
cooperation with other national and international companies working with the same objective
Its president, Dr. Carlos Aparicio, explains that "the real revolution of this century health through the increased level of responsibility of the individual in managing their own health. The minimally invasive guidance assumes that there are few things so precise and perfect as the human body to propose the conservation of the stomatognathic system in general, and the tooth with its supporting structures, in particular, both aesthetically and functionally.
All dental specialties continues Dr. Aparicio can use friendly processes: from prevention, arguably the most conservative treatment that we know, until surgery with implants. Any dentist, whatever their specialty should be interested in this working philosophy that seeks results of maximum efficiency with minimal intervention. In this regard, I am convinced that the practice of minimally invasive dentistry practice in Spanish consultations in the near future.
Seomi offers members the opportunity to access to exclusive services for innovation and quality in dentistry through meetings and publications of scientific, as well as the possibility of knowing the latest developments and case studies in the field of dentistry to www.seomi.org across the page. Furthermore, the Dental Associates have the opportunity to use the logo of the company in his office as a symbol of awareness for respect for the integrity of the patient.
Madrid hosts the second meeting of Seomi
The next few days 27 and 28 February, Seomi holds its second conference at the headquarters of the Meliá Avenida América with the aim of making known the benefits of this discipline and to encourage both general and specialist dentists adopt this philosophy of work daily clinical practice. This year the chairman of the meeting is Dr. Javier Alández.
Dr. Alández, says that with the title New Perspectives in Dentistry: The minimally invasive approach, the meeting in Madrid offers an attractive scientific program, with the presence of prominent international personalities in the field, most notably David Clark, founder of the Academy of Microscope Enhanced Dentistry, Marianella Sierraalta, Professor of Prosthodontics at the University of Michigan, Joao Caramés, professor at the Faculty of Dental Medicine, University of Lisbon; Shakibaie Behnam, MD of reference in Rheda-Wiedenbrueck / Germany in implantology and periodontics minimally invasive, and Giani Simon, Professor of Dentistry at the University of Insubria and University of Bologna. Next to them, are provided assistance from the national experts: Josune Antia, Radigales Manuel Antón, José María Aranguren, Patricia Gatón Andres Pascual, and Beatriz Rodriguez Vilaboa.
Thursday, October 29, 2009
Identified a region of chromosome 13 as a risk factor in Multiple Sclerosis.
It is published in the journal PLoS One:
This discovery is a breakthrough in understanding a disease that affects one in 1,000 people. The Research Institute of lHospital Universitari de la Vall dHebron presented as a benchmark in the latest scientific knowledge about the disease produced.
The research group in Neuroimmunology Clinical Research Institute of dHebron lHospital Barcelona Universitari Vall (IR-HUVH), led by Dr. Xavier Montalban, has participated in this study Multiple Sclerosis, a degenerative disease of origin unknown and no definitive cure. These results, published in the journal PloS One, acquire a top-level importance in the genetic knowledge of Multiple Sclerosis, and pointing to a new region on chromosome 13 as a risk factor for developing the disease. Moreover, not only contribute information to this effect, but the results also imply, most likely, a group of microRNAs located in this new region as key elements in the risk of developing the disease.
Multiple sclerosis is a neurodegenerative disease, chronic non-contagious and seriously affecting the mobility of the individual producing progressive disability. In fact, in Western countries, is the first most common cause of neurological disability. The symptoms appear when patients are between 20 and 40 years (most common neurological disease among young people, after epilepsy) and currently has no cure, although investigations have been started on drugs that could slow the process .
For this reason, the group of IR-HUVH Neuroimmunology focuses its research with the aim of improving the quality of life for patients with Multiple Sclerosis (MS) and deeper understanding of the pathogenic mechanisms of the disease, so develop new therapeutic treatments more effective. The success of this group lies in its direct involvement in the new advances in diagnosis, pathogenesis and therapy.
The study: a possible starting point for a new line of research
The IR-HUVH researchers conducted several previous steps until finally, they found two susceptibility genes of interest. First, they studied a group of 250 patients affected by Multiple Sclerosis (MS) and compared the results with control group of 250 healthy people in order to determine differences among some 500,000 polymorphisms within the genetic information. In particular, they studied what are called Snips-SNPs (Single Nucleotide Polimorphism) - or variants of the gene sequence for each individual, ie those most common variations, known and associated with our normal population. However, the polymorphisms studied 5000.000, and applying different criteria, differences were demonstrated between 384 SNPs.
Later, in a second step, these 384 genes were compared between 100 affected by MS and 100 healthy individuals. As a result of the comparison, there were Snips 8 genes that are expressed significantly in patients with sclerosis compared with healthy individuals.
Finally, a third step, no more validated SNPs 2 genes, one found in the HLA region (closely associated, by other studies, multiple sclerosis) and the other in another region that has not been associated with this disease before .
These results reinforce and give coherence to the study hypothesis, since, as already known for some time, there is a strong association between HLA genes and Multiple Sclerosis. The fact that one of the SNPs associated with disease is in the HLA region validates the methodology used in the study. Moreover, in recent decades, many researchers have attempted to identify new genes not associated with HLA but, so far, the results were not satisfactory enough. For this reason, researchers at the IR-HUVH offer thus an important step in identifying a new region located on chromosome 13q31.3 as a risk factor.
In this new area of concern identified include a group of microRNAs that may be responsible for risk of disease, explains Dr. Manel Comabella responsible for this study. These microRNAs are small molecules and proteins that do not translate that regulate the expression of other genes. MicroRNAs have been known for some time and its role in multiple sclerosis is unknown.
Similarly, another research group has found that the expression of some microRNAs in this region are different between patients with MS and individuals without the presence of the disease. This finding provides indirect evidence about the importance of this group of microRNAs, while reinforcing the importance of our findings, Dr. Comabella concrete. We are now studying how microRNAs influence this group and other genes that are very close to this region, the risk for this disease.
This discovery is a breakthrough in understanding a disease that affects one in 1,000 people. The Research Institute of lHospital Universitari de la Vall dHebron presented as a benchmark in the latest scientific knowledge about the disease produced.
The research group in Neuroimmunology Clinical Research Institute of dHebron lHospital Barcelona Universitari Vall (IR-HUVH), led by Dr. Xavier Montalban, has participated in this study Multiple Sclerosis, a degenerative disease of origin unknown and no definitive cure. These results, published in the journal PloS One, acquire a top-level importance in the genetic knowledge of Multiple Sclerosis, and pointing to a new region on chromosome 13 as a risk factor for developing the disease. Moreover, not only contribute information to this effect, but the results also imply, most likely, a group of microRNAs located in this new region as key elements in the risk of developing the disease.
Multiple sclerosis is a neurodegenerative disease, chronic non-contagious and seriously affecting the mobility of the individual producing progressive disability. In fact, in Western countries, is the first most common cause of neurological disability. The symptoms appear when patients are between 20 and 40 years (most common neurological disease among young people, after epilepsy) and currently has no cure, although investigations have been started on drugs that could slow the process .
For this reason, the group of IR-HUVH Neuroimmunology focuses its research with the aim of improving the quality of life for patients with Multiple Sclerosis (MS) and deeper understanding of the pathogenic mechanisms of the disease, so develop new therapeutic treatments more effective. The success of this group lies in its direct involvement in the new advances in diagnosis, pathogenesis and therapy.
The study: a possible starting point for a new line of research
The IR-HUVH researchers conducted several previous steps until finally, they found two susceptibility genes of interest. First, they studied a group of 250 patients affected by Multiple Sclerosis (MS) and compared the results with control group of 250 healthy people in order to determine differences among some 500,000 polymorphisms within the genetic information. In particular, they studied what are called Snips-SNPs (Single Nucleotide Polimorphism) - or variants of the gene sequence for each individual, ie those most common variations, known and associated with our normal population. However, the polymorphisms studied 5000.000, and applying different criteria, differences were demonstrated between 384 SNPs.
Later, in a second step, these 384 genes were compared between 100 affected by MS and 100 healthy individuals. As a result of the comparison, there were Snips 8 genes that are expressed significantly in patients with sclerosis compared with healthy individuals.
Finally, a third step, no more validated SNPs 2 genes, one found in the HLA region (closely associated, by other studies, multiple sclerosis) and the other in another region that has not been associated with this disease before .
These results reinforce and give coherence to the study hypothesis, since, as already known for some time, there is a strong association between HLA genes and Multiple Sclerosis. The fact that one of the SNPs associated with disease is in the HLA region validates the methodology used in the study. Moreover, in recent decades, many researchers have attempted to identify new genes not associated with HLA but, so far, the results were not satisfactory enough. For this reason, researchers at the IR-HUVH offer thus an important step in identifying a new region located on chromosome 13q31.3 as a risk factor.
In this new area of concern identified include a group of microRNAs that may be responsible for risk of disease, explains Dr. Manel Comabella responsible for this study. These microRNAs are small molecules and proteins that do not translate that regulate the expression of other genes. MicroRNAs have been known for some time and its role in multiple sclerosis is unknown.
Similarly, another research group has found that the expression of some microRNAs in this region are different between patients with MS and individuals without the presence of the disease. This finding provides indirect evidence about the importance of this group of microRNAs, while reinforcing the importance of our findings, Dr. Comabella concrete. We are now studying how microRNAs influence this group and other genes that are very close to this region, the risk for this disease.
New data confirm the remission of Crohn's disease
New data confirm the remission of Crohn's disease with the combined use of Remicade ® (infliximab) and azathioprine.
The results were made public during the Fourth Congress of the European Crohn's and Colitis Organization recently held in Hamburg Colitis
Around 69% of patients with Crohn's disease of moderate to severe and high levels of C reactive protein (CRP) and mucosal lesions go into remission with combination therapy of infliximab and azathioprine according to a subanalysis of the study SONIC
In Spain there are about 40,000 affected by Crohn's disease that first manifests itself in people between 15 and 30 years and are suffering from reduced quality of life
Results from a subanalysis of SONIC Phase III Study of Patients with Crohn's Disease, Naïve to Immunomodulators and Biologic Therapy among Patients suffering from these moderate to severe disease with high levels of C-reactive protein (CRP) have shown high rates of remission when treated with Remicade ® (infliximab), either alone or in combination with azathioprine. Specifically, 69% have achieved the goals of clinical disease remission and mucosal healing at week 26.
These figures confirm the main objectives set by the SONIC study that show how biological therapies that are based Remicade ® (infliximab) in combination therapy or monotherapy increased clinical remission of Crohn's disease and scarring of the mucosa after 26 weeks of treatment. 57% of all patients seen in the SONIC study who were treated with Remicade ® (infliximab) and azathioprine in combination achieved remission. This finding highlights on the 44% of patients reported treatment benefits only infliximab monotherapy and 31% of those who received only azathioprine.
Main results of the subgroup of patients analyzed
The results arising from this sub-analysis at 26 weeks of treatment SONIC study fall into three study groups:
Patients with elevated CRP levels and mucosal lesions (40% of patients observed):
or treatment with Remicade ® (infliximab) and azathioprine (69% remission), monotherapy with Remicade ® (infliximab) (57%), treatment with azathioprine (28%)
Patients who reported high levels of C-reactive protein (≥ 0.8 mg / dL), which account for 58%. In this case, the results recorded are:
or treatment with Remicade ® (infliximab) and azathioprine (64% remission), monotherapy with Remicade ® (infliximab) (48%), treatment with azathioprine (28%)
Patients with mucosal lesions (64% of patients observed in the study):
or treatment with Remicade ® (infliximab) and azathioprine (61% remission), monotherapy with Remicade ® (infliximab) (51%), treatment with azathioprine (30%)
According to Dr. Jean Frederic Colombel, Professor of Hepatogastroenterology Hospital Center of Lille, the results of the SONIC study have been very well received by gastroenterologists met in Hamburg, as they show some great benefits for patients and efficacy data and safety Remicade ® in the treatment of chronic inflammatory bowel disease remission by recording the inflammation and healing of mucosal lesions.
About SONIC
SONIC is a randomized clinical trial phase III, double-blind, designed to compare the efficacy and safety of Remicade ®, azathioprine monotherapy and combination therapy of both drugs in patients with Crohn's disease of moderate to severe and had not received treatments previously immunomodulators and biologic therapies. Of the total 508 patients who participated in the study, 170 were treated with azathioprine 2-2.5 mg / kg / day and placebo, 169 patients received REMICADE ® 5 mg / kg at weeks 0, 2, 6 and every 8 weeks then with placebo capsules and 169 patients received REMICADE ® 5 mg / kg and azathioprine 2 to 2.5 mg / kg for 30 weeks. 52% of patients were men with a mean age of 34 years with a mean disease duration of 2.3 years.
Crohn's Disease
Crohn's disease is a chronic inflammatory bowel disease that affects more than 400,000 people in Europe, over 40,000 of them registered in Spain. This disease is characterized by having a direct impact on quality of life for those affected because, besides suffering from hospitalization, surgery and loss of productivity, have episodes where they can get to having to urinate up to 25 times a day. It also gave the patient a disease that costs about as it is a chronic disease that, while not fatal, unpleasant symptoms that are a taboo subject among the general population.
Schering-Plow
Schering-Plow is a global pharmaceutical company dedicated to health care through scientific innovation. Through internal research and collaborations with partners, Schering-Plow researches, develops, manufactures and markets advanced drug therapies to help save lives and improve quality of life for many people around the world. For that the company applies its research and development of prescription and consumer products and animal health.
The mission of Schering-Plow and professional account with which everyone is "Winning the trust, day by day" of doctors, patients and customers. The Company is based in Kenilworth (New Jersey, USA). His website is http://www.schering-plough.com plough.es Spain.
The results were made public during the Fourth Congress of the European Crohn's and Colitis Organization recently held in Hamburg Colitis
Around 69% of patients with Crohn's disease of moderate to severe and high levels of C reactive protein (CRP) and mucosal lesions go into remission with combination therapy of infliximab and azathioprine according to a subanalysis of the study SONIC
In Spain there are about 40,000 affected by Crohn's disease that first manifests itself in people between 15 and 30 years and are suffering from reduced quality of life
Results from a subanalysis of SONIC Phase III Study of Patients with Crohn's Disease, Naïve to Immunomodulators and Biologic Therapy among Patients suffering from these moderate to severe disease with high levels of C-reactive protein (CRP) have shown high rates of remission when treated with Remicade ® (infliximab), either alone or in combination with azathioprine. Specifically, 69% have achieved the goals of clinical disease remission and mucosal healing at week 26.
These figures confirm the main objectives set by the SONIC study that show how biological therapies that are based Remicade ® (infliximab) in combination therapy or monotherapy increased clinical remission of Crohn's disease and scarring of the mucosa after 26 weeks of treatment. 57% of all patients seen in the SONIC study who were treated with Remicade ® (infliximab) and azathioprine in combination achieved remission. This finding highlights on the 44% of patients reported treatment benefits only infliximab monotherapy and 31% of those who received only azathioprine.
Main results of the subgroup of patients analyzed
The results arising from this sub-analysis at 26 weeks of treatment SONIC study fall into three study groups:
Patients with elevated CRP levels and mucosal lesions (40% of patients observed):
or treatment with Remicade ® (infliximab) and azathioprine (69% remission), monotherapy with Remicade ® (infliximab) (57%), treatment with azathioprine (28%)
Patients who reported high levels of C-reactive protein (≥ 0.8 mg / dL), which account for 58%. In this case, the results recorded are:
or treatment with Remicade ® (infliximab) and azathioprine (64% remission), monotherapy with Remicade ® (infliximab) (48%), treatment with azathioprine (28%)
Patients with mucosal lesions (64% of patients observed in the study):
or treatment with Remicade ® (infliximab) and azathioprine (61% remission), monotherapy with Remicade ® (infliximab) (51%), treatment with azathioprine (30%)
According to Dr. Jean Frederic Colombel, Professor of Hepatogastroenterology Hospital Center of Lille, the results of the SONIC study have been very well received by gastroenterologists met in Hamburg, as they show some great benefits for patients and efficacy data and safety Remicade ® in the treatment of chronic inflammatory bowel disease remission by recording the inflammation and healing of mucosal lesions.
About SONIC
SONIC is a randomized clinical trial phase III, double-blind, designed to compare the efficacy and safety of Remicade ®, azathioprine monotherapy and combination therapy of both drugs in patients with Crohn's disease of moderate to severe and had not received treatments previously immunomodulators and biologic therapies. Of the total 508 patients who participated in the study, 170 were treated with azathioprine 2-2.5 mg / kg / day and placebo, 169 patients received REMICADE ® 5 mg / kg at weeks 0, 2, 6 and every 8 weeks then with placebo capsules and 169 patients received REMICADE ® 5 mg / kg and azathioprine 2 to 2.5 mg / kg for 30 weeks. 52% of patients were men with a mean age of 34 years with a mean disease duration of 2.3 years.
Crohn's Disease
Crohn's disease is a chronic inflammatory bowel disease that affects more than 400,000 people in Europe, over 40,000 of them registered in Spain. This disease is characterized by having a direct impact on quality of life for those affected because, besides suffering from hospitalization, surgery and loss of productivity, have episodes where they can get to having to urinate up to 25 times a day. It also gave the patient a disease that costs about as it is a chronic disease that, while not fatal, unpleasant symptoms that are a taboo subject among the general population.
Schering-Plow
Schering-Plow is a global pharmaceutical company dedicated to health care through scientific innovation. Through internal research and collaborations with partners, Schering-Plow researches, develops, manufactures and markets advanced drug therapies to help save lives and improve quality of life for many people around the world. For that the company applies its research and development of prescription and consumer products and animal health.
The mission of Schering-Plow and professional account with which everyone is "Winning the trust, day by day" of doctors, patients and customers. The Company is based in Kenilworth (New Jersey, USA). His website is http://www.schering-plough.com plough.es Spain.
Subscribe to:
Posts (Atom)
